In a randomized , double-blind , placebo-controlled , parallel phase 2 , efficacy and safety study , eligible patients with moderate to severe LUTS and prostatic enlargement ( 30ml ) were randomized to placebo or LY500307 at 1 , 3 , 10 and 25mg once daily for 24 weeks .